Human Monoclonal antibodies against influenza: a map guiding towards a universal influenza vaccine?
Jaap Goudsmit, Chief Scientific Officer, Crucell
Terrapinn talks Vaccines
Panel session: Moving towards the reality of a universal influenza vaccine
Sarah Gilbert, Jenner Institute, Oxford University
Adjuvants – a strategic component in modern vaccine development
Karin Lövgren Bengtsson, Chief Scientific Officer, Isconova and Thomas Phillipson, Sales & Marketing Director, Isconova
Review of the 2010 World Health Organization recommendations for influenza vaccination composition
Yipu Lin, Assistant director of WHO collaborating centre for reference and research on Influenza
The changing regulatory landscape for influenza vaccines
Ed Geuns, Director, Regulatory Affairs, Vaccines EPD, Abbott Biologicals
Flu programme management in the UK
Prof. David Salisbury, Director of Immunisation, UK Department of Health
Communication efficacy across the vaccine delivery pipeline
Heather Richmond, CDC Liaison, MedImmune
Overcoming challenges in process development and manufacturing of vaccines for clinical trials
Stephen Cross, Process Development Scientist, Merck Millipore
HIV vaccine scientific progress and challenges
Hansi Dean, Director, New Alliances, International AIDS Vaccine Initiative (IAVI)
The role of MVI PATH and the responsibility to the developing world
Alex Adjagba, Program Officer, Health Economics and Policy, PATH Malaria Vaccine Initiative
Enabling manufacture of modern vaccines
Olivier Loeillot, Head of Enterprise Solutions, GE Healthcare
Understanding public trust in vaccination
Angus Thomson, Director, Global Immunisation Policy, sanofi pasteur
addressing significant unmet needs through world class vaccine pipelines
Matt Davis, University of Michigan and Christian Moser, Pevion Biotech
